|
Age | 66 岁 |
|
patients with coronary heart disease | Yes
|
|
Sign the informed consent | Yes
|
|
Risk stratification for patients with low or middle risk | low rrisk
|
|
Patients in one of the following condition are excluded | none
|
|
Name | ROYA |
|
gender | 女 |
|
people | 汉 |
|
Height | 158 cm |
|
weight | 53.3 kg |
|
abdomen circumference | 83 cm |
|
left ventricular ejection fraction(LVEF) | 65 |
|
stents implanted | Yes
|
|
anamnesis | hypertension
/heart failure
/none
|
|
Body Mass Index | 21.35 kg/m2 |
|
smoking history | No
|
|
blood cholesterol level in hospital | 5.6 mmol/l |
|
drink history | No
|
|
Bad mood performance | anxiety
|
|
exercise habit | No
|
|
The drug | antiplatelet drug
|
|
heart rate in anaerobic domain | 次/分 |
|
heart rate in the peak oxygen uptake | 79 次/分 |
|
blood pressure in Anaerobic domain | mm/Hg |
|
blood pressure in the peak oxygen uptake | 132/63 mm/Hg |
|
the oxygen uptake in the rest | 0.222 ml/kg/min |
|
the oxygen uptake in anaerobic threshold | ml/kg/min |
|
Peak oxygen uptake | 0.5387 ml/kg/min |
|
target heart rate | 75 次/分 |
|
Treadmill load | 25 w |
|
blood pressure in the rest | 62 次/分 |
|
blood pressure in the rest | 110/63 mm/Hg |
|
Phosphodiesterase 9A | ng/ml |
|
Inflammatory factors | ng/ml |
|
Immune-modulatory marker | ng/ml |
|
left ventricular dysfunction marker | ng/ml |
|
myeloperoxidase | ng/ml |
|
adiponectin | ng/ml |
|
extracellular-matrix remodeling markers | ng/ml |
|
heart rate in anaerobic domain | 次/分 |
|
heart rate in the peak oxygen uptake | 96 次/分 |
|
blood pressure in the rest | mm/Hg |
|
blood lipid level in Peak oxygen uptake period | 174/74 mm/Hg |
|
the oxygen uptake in the rest | 0.238 ml/kg/min |
|
the oxygen uptake in anaerobic threshold | ml/kg/min |
|
Peak oxygen uptake | 0.804 ml/kg/min |
|
target heart rate | 78 次/分 |
|
Treadmill load | 35 w |
|
heart rate in the rest | 66 次/分 |
|
blood pressure in the rest | 106/66 mm/Hg |
|
Phosphodiesterase 9A | ng/ml |
|
Inflammatory factors | ng/ml |
|
Immune-modulatory marker | ng/ml |
|
left ventricular dysfunction marker | ng/ml |
|
myeloperoxidase | ng/ml |
|
adiponectin | ng/ml |
|
extracellular-matrix remodeling markers | ng/ml |
|
Patients with follow-up of 3 months is discomfort or not | No
|
|
stick to exercise or not in the follow-up after 3 months | Yes
|